322 related articles for article (PubMed ID: 15261458)
1. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
2. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
3. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
4. Humanization by CDR grafting and specificity-determining residue grafting.
Kim JH; Hong HJ
Methods Mol Biol; 2012; 907():237-45. PubMed ID: 22907355
[TBL] [Abstract][Full Text] [Related]
5. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
[TBL] [Abstract][Full Text] [Related]
6. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences.
Singer II; Kawka DW; DeMartino JA; Daugherty BL; Elliston KO; Alves K; Bush BL; Cameron PM; Cuca GC; Davies P
J Immunol; 1993 Apr; 150(7):2844-57. PubMed ID: 8095956
[TBL] [Abstract][Full Text] [Related]
7. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
8. Use of human germline genes in a CDR homology-based approach to antibody humanization.
Hwang WY; Almagro JC; Buss TN; Tan P; Foote J
Methods; 2005 May; 36(1):35-42. PubMed ID: 15848073
[TBL] [Abstract][Full Text] [Related]
9. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
10. Minimizing the immunogenicity of antibodies for clinical application.
Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
[TBL] [Abstract][Full Text] [Related]
11. Designing human consensus antibodies with minimal positional templates.
Couto JR; Christian RB; Peterson JA; Ceriani RL
Cancer Res; 1995 Dec; 55(23 Suppl):5973s-5977s. PubMed ID: 7493379
[TBL] [Abstract][Full Text] [Related]
12. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
[TBL] [Abstract][Full Text] [Related]
13. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting.
Kim DS; Lee SH; Kim JS; Lee SC; Kwon MH; Kim YS
Biochem Biophys Res Commun; 2009 Feb; 379(2):314-8. PubMed ID: 19103171
[TBL] [Abstract][Full Text] [Related]
14. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
15. Engineering fully human monoclonal antibodies from murine variable regions.
Bernett MJ; Karki S; Moore GL; Leung IW; Chen H; Pong E; Nguyen DH; Jacinto J; Zalevsky J; Muchhal US; Desjarlais JR; Lazar GA
J Mol Biol; 2010 Mar; 396(5):1474-90. PubMed ID: 20045416
[TBL] [Abstract][Full Text] [Related]
16. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization.
Kim KS; Kim HJ; Han BW; Myung PK; Hong HJ
Biochem Biophys Res Commun; 2010 May; 396(2):231-7. PubMed ID: 20399745
[TBL] [Abstract][Full Text] [Related]
17. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2003 Oct; 40(6):337-49. PubMed ID: 14522015
[TBL] [Abstract][Full Text] [Related]
18. A germline knowledge based computational approach for determining antibody complementarity determining regions.
Zhao S; Lu J
Mol Immunol; 2010 Jan; 47(4):694-700. PubMed ID: 19939452
[TBL] [Abstract][Full Text] [Related]
19. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
20. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]